Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Profession Business and Innovation, Retina, Glaucoma

Business in Brief

Hope for uveitic ME patients

Bausch Health has acquired an exclusive license for the commercialization and development of Clearside’s XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) – an investigational treatment for macular edema (ME) associated with uveitis – in the US and Canada. NDA resubmission to the FDA is expected to occur in the first quarter of 2020.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Lauren Robertson

Deputy Editor at The Ophthalmologist.

Newsletter

Send me the latest from The Ophthalmologist.

Sign up now

Related Articles

Subspecialties Health Economics and Policy

The Ethics of AI

| Michael D. Abramoff, Pearse Keane, Stephen Odaibo, Daniel Ting

Subspecialties Business and Innovation

Through the Looking Glass

| Karim F. Damji

Subspecialties Cornea / Ocular Surface

A Nose for OSD

| Elizabeth Yeu

Most Popular

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register